ATE116335T1 - Peptid-analoge vom insulinähnlichen wachstums- faktor 1 (igf-1) oder faktor 2 (igf-2). - Google Patents

Peptid-analoge vom insulinähnlichen wachstums- faktor 1 (igf-1) oder faktor 2 (igf-2).

Info

Publication number
ATE116335T1
ATE116335T1 AT89900786T AT89900786T ATE116335T1 AT E116335 T1 ATE116335 T1 AT E116335T1 AT 89900786 T AT89900786 T AT 89900786T AT 89900786 T AT89900786 T AT 89900786T AT E116335 T1 ATE116335 T1 AT E116335T1
Authority
AT
Austria
Prior art keywords
growth factor
igf
acid residue
insulin
pct
Prior art date
Application number
AT89900786T
Other languages
English (en)
Inventor
Francis John Ballard
John Campbell Wallace
Julian Richard Este Wells
Original Assignee
Gropep Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gropep Pty Ltd filed Critical Gropep Pty Ltd
Application granted granted Critical
Publication of ATE116335T1 publication Critical patent/ATE116335T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT89900786T 1987-12-24 1988-12-20 Peptid-analoge vom insulinähnlichen wachstums- faktor 1 (igf-1) oder faktor 2 (igf-2). ATE116335T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPI606887 1987-12-24

Publications (1)

Publication Number Publication Date
ATE116335T1 true ATE116335T1 (de) 1995-01-15

Family

ID=3772677

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89900786T ATE116335T1 (de) 1987-12-24 1988-12-20 Peptid-analoge vom insulinähnlichen wachstums- faktor 1 (igf-1) oder faktor 2 (igf-2).

Country Status (7)

Country Link
US (1) US5164370A (de)
EP (1) EP0346429B1 (de)
JP (1) JP2507106B2 (de)
AT (1) ATE116335T1 (de)
CA (1) CA1341204C (de)
DE (1) DE3852636T2 (de)
WO (1) WO1989005822A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470828A (en) * 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
US6723699B1 (en) 1989-06-05 2004-04-20 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US6693076B1 (en) 1989-06-05 2004-02-17 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5652214A (en) * 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
EP0429586B1 (de) * 1989-06-09 1995-08-02 Gropep Pty. Ltd. Wachstumshormonfusionsproteine
US5045531A (en) * 1989-12-18 1991-09-03 Magainin Sciences Inc. Wound treatment employing biologically active ion channel forming peptides and proteins
US5679771A (en) * 1990-02-13 1997-10-21 Gropep Pty. Ltd. Method for treating intestinal diseases
ATE165008T1 (de) * 1990-02-13 1998-05-15 Gropep Pty Ltd Methode zur behandlung intestinaler krankheiten
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
SE9002732D0 (sv) * 1990-08-24 1990-08-24 Kabivitrum Ab Product containing growth factor
SE9002731D0 (sv) * 1990-08-24 1990-08-24 Kabivitrum Ab Product comprising growth factor
US5744139A (en) * 1991-06-28 1998-04-28 University Of Tennessee Research Corporation Insulin-like growth factor I (IGF-1) induced improvement of depressed T4/T8 ratios
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
US5736363A (en) * 1991-07-29 1998-04-07 British Bio-Technology Limited IGF-II analogues
EP0607278B1 (de) * 1991-10-07 2002-04-17 The Brigham And Women's Hospital, Inc. Verfahren zur erhöhung der darmabsorption
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
JPH07508025A (ja) * 1992-05-08 1995-09-07 トーマス・ジェファーソン・ユニバーシティ インスリン様増殖因子（ｉｇｆ−１）類似体
CA2114419A1 (en) * 1992-06-08 1993-12-23 Peter D. Gluckman Use of growth factor igf-i and/or igf-ii
NZ260309A (en) * 1992-06-08 1997-07-27 Pharmacia Ab Substituted For K Use of 1gf-2 for prevention or treatment of nutritional or gastrointestinal disorders and promoting neonatal growth
JP3623502B2 (ja) * 1992-06-12 2005-02-23 セファロン，インコーポレイテッド 末梢神経障害の予防および治療
US5420112A (en) * 1992-06-12 1995-05-30 Lewis; Michael E. Prevention and treatment of peripheral neuropathy
US5444045A (en) * 1992-09-17 1995-08-22 Gropep, Pty. Ltd. Method of administering IGF-1, IGF-2, and analogs thereof to birds
GB9310049D0 (en) * 1993-05-12 1993-06-30 Cancer Res Campaign Tech Growth factor effects
CA2172158A1 (en) * 1993-09-20 1995-03-30 Joseph A. Carlino Treatment of immunologic and hematologic disorders with igfbp alone or complexed with igf
CA2265972A1 (en) * 1996-09-16 1998-03-26 Philip D. Acott Use of igf-i for the treatment of polycystic kidney disease and related indications
US6156728A (en) * 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6358916B1 (en) 1998-07-22 2002-03-19 Thomas T. Chen Biological activity of IGF-I E domain peptide
US7118752B2 (en) 1998-07-22 2006-10-10 University Of Connecticut Compositions and methods for inhibiting the proliferation and invasiveness of malignant cells comprising E-domain peptides of IGF-I
US7700353B2 (en) 1998-07-22 2010-04-20 E-P Therapeutics, Inc. Compositions and methods for inducing apoptosis in tumor cells
DE60042550D1 (de) * 1999-01-06 2009-08-27 Genentech Inc Mutierte varianten des insulin-ähnlichen wachstumsfaktor i (igf-i)
PT1141014E (pt) 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
EP1506972A1 (de) * 1999-01-06 2005-02-16 Genentech Inc. Mutierte Varianten des Insulin-ähnlichen Wachstumsfaktor-I (IGF-I)
AU763039B2 (en) * 1999-04-08 2003-07-10 Genentech Inc. Composition based on oppositely-charged polypeptides
ES2301547T3 (es) 2000-05-16 2008-07-01 Genentech, Inc. Tratamiento de trastornos del cartilago.
NZ548358A (en) * 2001-02-09 2008-04-30 Genentech Inc Method of identifying agonists of insulin-like growth factor-1
US7071300B2 (en) * 2001-03-14 2006-07-04 Genentech, Inc. IGF antagonist peptides
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
AU2002303856A1 (en) 2001-05-24 2002-12-03 Neuronz Limited Gpe analogs and peptidomimetics
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
WO2003039232A2 (en) * 2001-10-26 2003-05-15 Large Scale Biology Corporation Endothelial cell derived hemotopoietic growth factor
US7439063B2 (en) * 2002-06-11 2008-10-21 Burnham Institute For Medical Research Neuroprotective synergy of erythropoietin and insulin-like growth factors
ATE536186T1 (de) 2003-09-12 2011-12-15 Tercica Inc Verfahren zur behandlung von igf-1 (insulin-like growth factor 1)-mangel
WO2005033134A2 (en) * 2003-09-30 2005-04-14 Regeneron Pharmaceuticals, Inc. Secreted protein therapeutics and uses thereof
EP1670822A2 (de) * 2003-10-03 2006-06-21 Genentech, Inc. Igf-bindende proteine
EP1674113A1 (de) * 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Konjugate von insulinähnlichem Wachstumfaktor-1 und Poly(Ethylenglykol)
EP1841443A4 (de) * 2005-01-11 2012-05-02 Heart Failure Technologies Inc Verfahren und system zur behandlung von herzfehlern
TWI406870B (zh) * 2005-02-21 2013-09-01 Chugai Pharmaceutical Co Ltd A method of making a protein using hamster IGF-1
CL2007001614A1 (es) 2006-06-09 2008-08-08 Novartis Ag Polipeptido que comprende una proteina del precursor del factor de crecimiento tipo insulina, igf-1 humana, en la cual la escision del peptido e mediante una proteasa se reduce a traves de la modificacion de la proteina del precursor; y su uso para t
US20120093775A1 (en) 2009-03-27 2012-04-19 Proyecto De Biomedicina Cima, S.L. Methods and compositions for the treatment of cirrhosis and liver fibrosis
PL3344758T3 (pl) 2015-09-01 2022-01-03 Ncardia B.V. Sposób in vitro różnicowania populacji ludzkich pluripotentnych komórek macierzystych w populację komórek kardiomiocytów
WO2021005604A1 (en) 2019-07-11 2021-01-14 Opko Biologics Ltd. Long-acting igf-1 or igf-1 variants and methods of producing same
WO2024010727A2 (en) * 2022-07-05 2024-01-11 Terasaki Institute For Biomedical Innovation Cell growth supplements using dairy-based materials

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US408518A (en) * 1889-08-06 Stilt
US4196167A (en) * 1978-12-26 1980-04-01 California Medical Developments, Inc. Drug detection device
WO1985000831A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of insulin-like growth factor
US4745179A (en) * 1984-04-02 1988-05-17 Fujisawa Pharmaceutical Co., Ltd. 59 Valine insulin-like growth factor I and process for production thereof
SE8403479L (sv) * 1984-06-29 1986-01-29 Ssab Svenskt Stal Ab Sett att framstella profilerade stenger
JPH0720993B2 (ja) * 1985-08-22 1995-03-08 グロペップ プロプライエタリー リミテッド 生長因子
SE8505920D0 (sv) * 1985-12-13 1985-12-13 Kabigen Ab New protein and its use
US4876242A (en) * 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
CA2007886A1 (en) * 1989-01-17 1990-07-17 Marvin L. Bayne Human insulin-like growth factor analogs with reduced binding to 28 k igf binding proteins and their production in yeast

Also Published As

Publication number Publication date
WO1989005822A1 (en) 1989-06-29
JP2507106B2 (ja) 1996-06-12
EP0346429A1 (de) 1989-12-20
DE3852636D1 (de) 1995-02-09
JPH02504279A (ja) 1990-12-06
AU612776B2 (en) 1991-07-18
EP0346429A4 (en) 1990-10-10
US5164370A (en) 1992-11-17
AU2900989A (en) 1989-07-19
DE3852636T2 (de) 1995-05-04
CA1341204C (en) 2001-03-13
EP0346429B1 (de) 1994-12-28

Similar Documents

Publication Publication Date Title
ATE116335T1 (de) Peptid-analoge vom insulinähnlichen wachstums- faktor 1 (igf-1) oder faktor 2 (igf-2).
AU6286986A (en) Peptide analogues of mammalian insulin-like growth factor-1
DE69016655D1 (de) Biologisch aktive polypeptide, die auf transformierten wachstumsfaktor-beta-sequenzen basieren.
ATE121755T1 (de) Deletionsanaloga von magaininpeptiden.
ATE213499T1 (de) Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose
ATE377026T1 (de) Behandlung von fettleibigkeit
ATE146188T1 (de) Substituierungsanaloge von magaininpeptiden
NZ224028A (en) Bovine growth hormone analogue compositions and animals
MX167236B (es) Peptidos sinteticos de timosina -1 y metodo para su obtencion
DK0561877T3 (da) Forbindelser og præparater der hæmmer knogleresorption
AR004497A1 (es) Un análogo hexapéptido cíclico de somatostatina, procedimiento para prepararlos y las composiciones farmacéuticas que los contienen y el uso de dicho hexapéptido para la preparación de una composición farmacéutica.
EP0282318A3 (de) Analog des Rinderwachstumshormons
BR8807658A (pt) Peptideos tendo homologia estrutural, formulacao antigena farmaceutica e processo para alterar as caracteristicas de um vertebrado
KR890700673A (ko) 돼지 성장호르몬 아날로그
NO881661L (no) Humane rhinoviruspeptider.
SE8703855D0 (sv) Vasoaktiva peptider
GB1119353A (en) Peptides having an adrenocorticotropic hormone action and process for their manufacture
AR247473A1 (es) Una composicion que produce una respuesta lactogenica o crecimiento en ganado bovino, excluidas todas sus aplicaciones terapeuticas
JPS5750948A (en) Insulin analog and preparation
DK661888A (da) Biologisk aktive molekyler
TH21046B (th) ฮอร์โมนเทียมเพื่อการเจริญเติบโตของหมู

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee